Ting Fu
Directeur/Membre du Conseil chez Taizhou EOC Pharma Co., Ltd.
Profil
Ting Fu is currently working as a Director at Taizhou EOC Pharma Co., Ltd.
She completed her graduate degree from the University of Southern California in 2016 and her undergraduate degree from China Pharmaceutical University in 2014.
Postes actifs de Ting Fu
| Sociétés | Poste | Début |
|---|---|---|
Taizhou EOC Pharma Co., Ltd.
 Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Directeur/Membre du Conseil | 26/11/2019 |
Formation de Ting Fu
| China Pharmaceutical University | Undergraduate Degree |
| University of Southern California | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |
